William Blair analyst Ryan Daniels has maintained their bullish stance on HNGE stock, giving a Buy rating on November 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors that highlight Hinge Health’s strong financial performance and growth potential. The company reported impressive third-quarter results, exceeding revenue expectations and demonstrating significant operating leverage. This was evident in a 56% beat on operating income compared to consensus estimates, and a 50% growth in trailing-12-month billings, indicating robust momentum.
Moreover, management has raised their 2025 guidance across key metrics, reflecting confidence in sustained growth. Despite a temporary dip in share prices, Daniels suggests that investors should focus on the company’s long-term prospects. Hinge Health is well-positioned to benefit from the increasing demand for digital musculoskeletal (MSK) solutions, driven by employers seeking cost-effective and employee-friendly healthcare options. The company’s continued innovation, particularly in AI-enabled care, further solidifies its market leadership and potential for future growth.
Daniels covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, TransMedics Group, and Addus Homecare. According to TipRanks, Daniels has an average return of 8.5% and a 50.31% success rate on recommended stocks.
In another report released on November 3, Barclays also maintained a Buy rating on the stock with a $62.00 price target.